

# Federico Pea

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5729880/federico-pea-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232  
papers

5,656  
citations

35  
h-index

68  
g-index

240  
ext. papers

6,974  
ext. citations

5.7  
avg, IF

6.05  
L-index

#	Paper	IF	Citations
232	Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring.. <i>Infectious Disease Reports</i> , <b>2022</b> ,	0.6	1
231	Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases.. <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	0
230	Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant (DTR-P) infections.. <i>JAC-Antimicrobial Resistance</i> , <b>2021</b> , 3, dlab188	2.9	4
229	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 11, 635	6.2	1
228	A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant <i>Acinetobacter baumannii</i> bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. <i>Journal of Global Antimicrobial Resistance</i> , <b>2021</b> , 27, 294-298	3.4	9
227	Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?". <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , AAC0190821	5.9	1
226	Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> in a critically ill patient. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 113, 213-217	10.5	5
225	Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 58, 106445	14.3	0
224	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 1	6.2	0
223	Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	6
222	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 19, 1125-1134	5.5	3
221	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. <i>CNS Drugs</i> , <b>2021</b> , 35, 345-384	6.7	3
220	Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> ,	5.9	2
219	Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> ,	5.9	11
218	Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 583-599	3.8	13
217	AuthorsPReply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6". <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 833-834	6.2	
216	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	18

215	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 19, 1373-1383	5.5	1
214	An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAls Caused by in Critically Ill Adult Patients. <i>Infection and Drug Resistance</i> , <b>2021</b> , 14, 2461-2498	4.2	1
213	Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1271-1289	6.2	7
212	Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections. <i>Current Opinion in Infectious Diseases</i> , <b>2021</b> , 34, 737-747	5.4	4
211	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 1837-1885	6.2	10
210	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. <i>Hematological Oncology</i> , <b>2021</b> , 39, 20-26	1.3	
209	The role of procalcitonin in reducing antibiotics across the surgical pathway. <i>World Journal of Emergency Surgery</i> , <b>2021</b> , 16, 15	9.2	0
208	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis. <i>Mycoses</i> , <b>2021</b> , 64, 1317-1327	5.2	0
207	Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. <i>Drug Design, Development and Therapy</i> , <b>2021</b> , 15, 3349-3378	4.4	8
206	Challenges in the management of chronic wound infections. <i>Journal of Global Antimicrobial Resistance</i> , <b>2021</b> , 26, 140-147	3.4	6
205	A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 755075	5.6	1
204	An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 1-22	5.5	1
203	Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 58, 106408	14.3	2
202	Impact of Maximizing C <sub>ss</sub> /MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 761888	5.6	4
201	An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by and in Critically Ill Adult Patients.. <i>Antibiotics</i> , <b>2021</b> , 11,	4.9	2
200	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1127-1153	14.5	184
199	From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis. <i>Mycoses</i> , <b>2020</b> , 63, 854-858	5.2	2
198	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e474-e484	14.2	583

197	Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 349-352	3.2	3
196	A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 186, 113273	3.5	25
195	The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 415-422	5.5	12
194	Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. <i>Journal of Infection and Chemotherapy</i> , <b>2020</b> , 26, 900-907	2.2	5
193	Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?. <i>Clinical Microbiology and Infection</i> , <b>2020</b> , 26, 1024-1033	9.5	13
192	Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 137-149	6.2	16
191	Assessment of the impact of clinical recommendations on antibiotic use for CAP and HCAP: results from an implementation program in an Academic Hospital. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , <b>2020</b> , 32, 344-356	0.9	0
190	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , <b>2020</b> , 13, 4697-4711	4.2	12
189	Acute wound infections management: the DonRsP from a multidisciplinary expert panel. <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 231-240	5.5	5
188	Sonidegib for the Treatment of Advanced Basal Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 582866	5.3	7
187	Tocilizumab in COVID-19: finding the optimal route and dose - AuthorsPreply. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e739-e740	14.2	2
186	Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3029-3037	5.1	11
185	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	3
184	Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1251-1260	6.2	16
183	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3588-3595	5.1	12
182	Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 819-827	5.5	10
181	Ceftobiprole: drug evaluation and place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 689-698	5.5	22
180	Treatment of Candida infections with fluconazole in adult liver transplant recipients: Is TDM-guided dosing adaptation helpful?. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13113	2.7	8

179	Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	27
178	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies <b>2019</b> , 892-896.e1		1
177	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1648-1655	5.1	5
176	A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2019</b> , 23, 1042	2.1	1
175	Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 657-664	3.2	4
174	Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 266-269	3.8	7
173	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , <b>2018</b> , 16, 307-320	5.5	65
172	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , <b>2018</b> , 30, 157-171	2.3	
171	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1091-1092	2.8	3
170	Actoxumab + bezlotoxumab combination: what promise for <i>Clostridium difficile</i> treatment?. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 469-476	5.4	4
169	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 1399-1405	6.2	10
168	Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 177-189	6.2	17
167	Ceftolozane/tazobactam for the treatment of MDR <i>Pseudomonas aeruginosa</i> left ventricular assist device infection as a bridge to heart transplant. <i>Infection</i> , <b>2018</b> , 46, 263-265	5.8	16
166	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 989-1000	6.2	12
165	Physiological Manifestations of Critical Illness <b>2018</b> , 31-46		0
164	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1449-1459	2.8	4
163	Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2544-2550	3.8	15
162	Is meropenem MIC increase against KPC-producing <i>Klebsiella pneumoniae</i> correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. <i>Journal of Global Antimicrobial Resistance</i> , <b>2018</b> , 14, 238-241	3.4	4

161	Procalcitonin-guided antibiotic therapy: an expert consensus. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2018</b> , 56, 1223-1229	5.9	34
160	Overview of antifungal dosing in invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, i33-i43	5.1	26
159	Pharmacokinetics and drug metabolism of antibiotics in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 1087-1100	5.5	15
158	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1671-1672	2.8	3
157	Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. <i>Drugs and Therapy Perspectives</i> , <b>2018</b> , 34, 402-403	1.5	1
156	A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 303-308	3.1	39
155	Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 23-28	14.3	7
154	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	14
153	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing <i>Klebsiella pneumoniae</i> ?. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 49, 255-258	14.3	50
152	βBlockers and Diltiazem Combination-Bear in Mind the Risk of Heart Block. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1543-1544	11.5	2
151	Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 1193-1200	5.5	16
150	Pharmacodynamics of teicoplanin against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 3382-3389	3.389	26
149	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. <i>Journal of NeuroVirology</i> , <b>2017</b> , 23, 908-912	3.9	5
148	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	25
147	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2342-2350	5.1	17
146	Reply: Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. <i>Annals of Pharmacotherapy</i> , <b>2016</b> , 50, 153	2.9	
145	Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1507-1520	6.2	28
144	Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 474-9	3.1	32

143	Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1323-9	5.1	11
142	Immunologic and Pharmacologic Aspects in an Elderly Recipient of Liver Transplant With Pulmonary Aspergillosis and Multiple Comorbidities. <i>Experimental and Clinical Transplantation</i> , <b>2016</b> , 14, 567-570	0.8	2
141	Monitoring Polypharmacy in Healthcare Systems Through a Multi-Setting Survey: Should We Put More Attention on Long Term Care Facilities?. <i>Journal of Public Health Research</i> , <b>2016</b> , 5, 745	2.2	6
140	Urological infections due to multidrug-resistant bacteria: what we need to know?. <i>Urologia</i> , <b>2016</b> , 83, 21-6	1.2	2
139	Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , <b>2016</b> , 29, 153-9	5.4	17
138	A 1-year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 341-8	3.8	15
137	Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 1070-8	2.6	18
136	Methicillin-resistant <i>Staphylococcus aureus</i> infections: A review of the currently available treatment options. <i>Journal of Global Antimicrobial Resistance</i> , <b>2016</b> , 7, 178-186	3.4	62
135	Risk factors associated with the onset of daptomycin non-susceptibility in <i>Staphylococcus aureus</i> infections in critically ill patients. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 366-8	14.5	12
134	Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections. <i>Expert Review of Anti-Infective Therapy</i> , <b>2015</b> , 13, 927-37	5.5	
133	Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5535-41	5.9	11
132	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 978-85	2.9	7
131	Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. <i>Current Opinion in Pharmacology</i> , <b>2015</b> , 24, 18-22	5.1	9
130	Comparison of clinical characteristics of tuberculosis between two age groups at an Italian Tertiary Hospital. <i>Infection</i> , <b>2015</b> , 43, 361-6	5.8	2
129	Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 933-41	6.2	23
128	Is empiric daptomycin effective in reducing mortality in <i>Staphylococcus aureus</i> bacteraemia? A real-life experience. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 2026-8	14.5	6
127	Linezolid underexposure in a patient co-treated with venlafaxine. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1285-6	2.8	7
126	A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolated from patients with bloodstream infections in Northeast Italy. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2015</b> , 81, 53-6	2.9	5

125	Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 198-206	5.1	22
124	Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 60, 1459-63	5.9	15
123	Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases. <i>Transplant Infectious Disease</i> , <b>2015</b> , 17, 147-53	2.7	4
122	Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. <i>Transplant Infectious Disease</i> , <b>2015</b> , 17, 926-8	2.7	5
121	Treatment options for community-acquired pneumonia in the elderly people. <i>Expert Review of Anti-Infective Therapy</i> , <b>2015</b> , 13, 473-85	5.5	7
120	Drugs and Blood Cells <b>2015</b> , 111-147		
119	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 2585-6	5.1	15
118	An international, multicentre survey of $\beta$ -lactam antibiotic therapeutic drug monitoring practice in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 1416-23	5.1	144
117	Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2014</b> , 115, 432-7	3.1	4
116	Daptomycin in solid organ transplantation: consideration of dosage adjustments in renal impairment. <i>Transplant Infectious Disease</i> , <b>2014</b> , 16, 868-9	2.7	1
115	Levofloxacin dosing regimen in severely morbidly obese patients (BMI $\geq$ 40 kg/m <sup>2</sup> ) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 753-62	6.2	23
114	Population pharmacokinetics of teicoplanin in children. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6920-7	5.9	21
113	Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 567-8	5.1	2
112	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 501-11	3.7	21
111	Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 687-9	3.2	9
110	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. <i>International Journal of Antimicrobial Agents</i> , <b>2014</b> , 44, 570-1	14.3	7
109	The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. <i>Advanced Drug Delivery Reviews</i> , <b>2014</b> , 77, 3-11	18.5	242
108	Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 674-6	3.2	20



107	Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. <i>Infection</i> , <b>2014</b> , 42, 207-10	5.8	15
106	Gentamicin once-daily in enterococcal endocarditis. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 5033-4	4.2	10
105	Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 989-97	5.5	7
104	The clinical relevance of plasma protein binding changes. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 1-8	6.2	173
103	Occurrence and extent of bruising according to duration of administration of subcutaneous low-molecular-weight heparin: a quasi-experimental case-crossover study. <i>Journal of Cardiovascular Nursing</i> , <b>2013</b> , 28, 473-82	2.1	17
102	Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 6081-4	5.9	21
101	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. <i>Current Clinical Pharmacology</i> , <b>2013</b> , 8, 5-12	2.5	1
100	Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients. <i>Current Clinical Pharmacology</i> , <b>2013</b> , 8, 5-12	2.5	2
99	Plasma pharmacokinetics of antimicrobial agents in critically ill patients. <i>Current Clinical Pharmacology</i> , <b>2013</b> , 8, 5-12	2.5	36
98	Antibiotic therapy in hematological neutropenic patients: what is the news?. <i>Leukemia Supplements</i> , <b>2012</b> , 1, S20-1	75	
97	Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 6343-8	5.9	61
96	Pneumonia in frail older patients: an up to date. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 415-24	3.7	20
95	Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 17-24	5.1	151
94	Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3438-40	5.9	16
93	Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2034-42	5.1	153
92	Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 2463-71	1.1	19
91	Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 1119-22	1.1	17
90	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. <i>World Journal of Emergency Surgery</i> , <b>2011</b> , 6, 2	9.2	51

89	HIV-infected patients and liver transplantation: who, when and why. <i>Current HIV Research</i> , <b>2011</b> , 9, 120-7.	1.3	7
88	Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4496; author reply 4496-7	5.9	2
87	TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. <i>Annals of Pharmacotherapy</i> , <b>2011</b> , 45, e37	2.9	43
86	Vancomycin Way of Administration: Where is the Evidence?. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 308-10; author reply 310	11.6	5
85	Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4605-10	5.9	133
84	Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. <i>International Journal of Infectious Diseases</i> , <b>2010</b> , 14 Suppl 4, S79-92	10.5	79
83	A multi-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory	10.5	1
82	Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group on Severe Infections). Is the use of vancomycin doses of at least 1 g every 8 hours the only way to achieve optimal trough levels in critically ill trauma patients with pneumonia and normal renal function?. <i>Journal of Trauma</i> , <b>2010</b> , 68, 748-9		
81	What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3608-9; author reply 609-10	5.9	6
80	Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1863-7	5.9	104
79	Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin?. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 642-3; author reply 643-5	11.6	6
78	The Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics: recommendations of the Italian Society of Chemotherapy. <i>Journal of Chemotherapy</i> , <b>2009</b> , 21, 475-81	2.3	2
77	Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?. <i>Critical Care</i> , <b>2009</b> , 13, 214	10.8	127
76	Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. <i>International Journal of Antimicrobial Agents</i> , <b>2009</b> , 33, 379-82	14.3	29
75	Penetration of Antibacterials into Bone. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 125-127	6.2	13
74	Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 135-6	3.2	2
73	Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia?. <i>Journal of Trauma</i> , <b>2009</b> , 67, 893-4; author reply 894-5		5
72	Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 167-9	5.1	8

71	Principles of Pharmacodynamics and Pharmacokinetics of Drugs Used in Extracorporeal Therapies <b>2009</b> , 1190-1194		
70	Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients?. <i>Anaesthesia and Intensive Care</i> , <b>2009</b> , 37, 323-4	1.1	5
69	Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 125-7	6.2	4
68	Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 147-52	6.2	25
67	Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 449-62	6.2	23
66	Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 1711-6	2.9	22
65	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 739-42	1.6	1
64	Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 739-742	1.6	5
63	Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. <i>Pharmacological Research</i> , <b>2007</b> , 55, 38-41	10.2	19
62	Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. <i>Clinical Pharmacokinetics</i> , <b>2007</b> , 46, 997-1038	6.2	137
61	What does it mean: appropriate therapy for methicillin-resistant Staphylococcus aureus?. <i>Critical Care Medicine</i> , <b>2007</b> , 35, 991; author reply 991-2	1.4	1
60	Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2007</b> , 58, 137-9	2.9	17
59	Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. <i>Expert Review of Anti-Infective Therapy</i> , <b>2007</b> , 5, 255-70	5.5	13
58	Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 434-5	11.6	62
57	The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 1764-71	11.6	111
56	Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 58, 380-6	5.1	42
55	Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 287-95	6.2	10
54	Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery. <i>International Journal of Antimicrobial Agents</i> , <b>2006</b> , 27, 15-9 <sup>14.3</sup>		3

53	The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin. <i>International Journal of Antimicrobial Agents</i> , <b>2006</b> , 27, 344-50	14.3	13
52	Treatment of post-traumatic hand Staphylococcus aureus osteomyelitis with oral linezolid. <i>Journal of Chemotherapy</i> , <b>2006</b> , 18, 425-9	2.3	1
51	Focus on antibiotics: use and misuse in the intensive care unit, and antibiotics monitoring <b>2006</b> , 179-184		
50	Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 1009-34	6.2	221
49	Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. <i>Contributions To Nephrology</i> , <b>2005</b> , 147, 35-46	1.6	44
48	Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 3550-3	5.9	41
47	Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 2554-7	5.9	10
46	Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 44, 1097-102	7.4	31
45	Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 405-15	6.2	66
44	Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients. <i>Journal of Chemotherapy</i> , <b>2004</b> , 16 Suppl 2, 8-10	2.3	6
43	Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 3104-8	5.9	41
42	Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 101-6	5.1	24
41	Antimicrobial agents in elective surgery: prophylaxis or "early therapy"? <i>Journal of Chemotherapy</i> , <b>2003</b> , 15, 3-11	2.3	6
40	Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. <i>Journal of Chemotherapy</i> , <b>2003</b> , 15, 563-7	2.3	13
39	Quale Ruolo per i Fluorochinoloni in Terapia Intensiva?. <i>Journal of Chemotherapy</i> , <b>2003</b> , 15, 5-10	2.3	9
38	What is the role of fluoroquinolones in intensive care?. <i>Journal of Chemotherapy</i> , <b>2003</b> , 15 Suppl 3, 5-10	2.3	8
37	Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. <i>Clinical Pharmacokinetics</i> , <b>2003</b> , 42, 589-98	6.2	48
36	Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia. <i>Clinical Pharmacokinetics</i> , <b>2003</b> , 42, 851-62	6.2	7

35	Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 971-5	5.1	97
34	MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma. <i>Fundamental and Clinical Pharmacology</i> , <b>2002</b> , 16, 519-25	3.1	1
33	TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. <i>International Journal of Antimicrobial Agents</i> , <b>2002</b> , 20, 326-32	14.3	44
32	Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, e109-11	11.6	28
31	Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. <i>Clinical Pharmacokinetics</i> , <b>2001</b> , 40, 833-68	6.2	96
30	Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. <i>Pharmacological Research</i> , <b>2001</b> , 43, 547-51	10.2	3
29	Protocol implementation in hospital infection control practice: an Italian experience of preoperative antibiotic prophylaxis. <i>Journal of Hospital Infection</i> , <b>2001</b> , 47, 288-93	6.9	11
28	Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 3151-3	1.1	2
27	Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 587-8	3.2	20
26	Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2000</b> , 46, 279-86	3.5	23
25	High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2000</b> , 45, 329-35	5.1	87
24	Optimisation of Vancomycin Regimen in Neutropenic Haematological Patients with Normal Renal Function. <i>Clinical Drug Investigation</i> , <b>2000</b> , 19, 213-218	3.2	9
23	Systemic vancomycin overexposure in a patient with spinal cord injury who had Staphylococcal sepsis and Clostridium difficile colitis. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 233-4	3.2	5
22	Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 386-91	3.2	7
21	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. <i>British Journal of Haematology</i> , <b>1999</b> , 106, 92-9	4.5	42
20	Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. <i>European Journal of Clinical Pharmacology</i> , <b>1999</b> , 55, 361-8	2.8	18
19	Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. <i>Pharmacological Research</i> , <b>1999</b> , 40, 483-6	10.2	5
18	Isoniazid and its Hydrazine Metabolite in Patients with Tuberculosis. <i>Clinical Drug Investigation</i> , <b>1999</b> , 17, 145-154	3.2	11

17	Pharmacokinetic Profile of Two Different Administration Schemes of Teicoplanin. <i>Clinical Drug Investigation</i> , <b>1999</b> , 18, 47-55	3.2	4
16	Effect of the number of samples on Bayesian and non-linear least-squares individualization: a study of cyclosporin treatment of haematological patients with multidrug resistance. <i>Journal of Pharmacy and Pharmacology</i> , <b>1998</b> , 50, 343-9	4.8	6
15	Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. <i>Leukemia</i> , <b>1998</b> , 12, 1236-40	10.7	20
14	Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. <i>Pharmacological Research</i> , <b>1997</b> , 35, 313-5	10.2	25
13	Oral gabapentin disposition in patients with epilepsy after a high-protein meal. <i>Epilepsia</i> , <b>1997</b> , 38, 1140-4	2.4	14
12	Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis. <i>Pharmacological Research</i> , <b>1996</b> , 33, 349-52	10.2	10
11	Blood concentrations and clinical effect of cyclosporin in psoriasis. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 544-8	3.2	16
10	Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by Bayesian and non-linear least squares methods. <i>Pharmacological Research</i> , <b>1995</b> , 32, 355-62	10.2	16
9	Prediction of cyclosporine blood concentrations in hematological patients with multidrug resistance. <i>Pharmacological Research</i> , <b>1995</b> , 31, 44	10.2	2
8	Study on the bactericidal activity and synergistic effect of neutropenic rat serum with gentamicin. <i>Journal of Chemotherapy</i> , <b>1994</b> , 6, 117-20	2.3	
7	Effect of fluctuations of blood cyclosporine concentrations on renal function. <i>Transplantation Proceedings</i> , <b>1994</b> , 26, 2574-5	1.1	3
6	Comparison of the antibacterial activity and synergistic activity towards antibiotics of different mammalian sera. <i>Journal of Chemotherapy</i> , <b>1993</b> , 5, 10-3	2.3	1
5	Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. <i>Biomaterials</i> , <b>1993</b> , 14, 1154-60	15.6	189
4	A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers. <i>Drug Investigation</i> , <b>1992</b> , 4, 391-394		
3	Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA. <i>Pharmacological Research</i> , <b>1992</b> , 25 Suppl 1, 85-6	10.2	2
2	Enhancement of in-vitro activity of ofloxacin and gentamicin by rat serum. <i>Journal of Chemotherapy</i> , <b>1990</b> , 2, 368-70	2.3	4
1	Nosocomial Pneumonia: Strategies for Management: General Pharmacological Considerations and Dose Adjustment in Antibiotic Therapy for HAP173-189		